<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366182">
  <stage>Registered</stage>
  <submitdate>16/04/2014</submitdate>
  <approvaldate>1/05/2014</approvaldate>
  <actrnumber>ACTRN12614000449639</actrnumber>
  <trial_identification>
    <studytitle>The significance of hyperglycaemia in survivors of critical illness and potential mechanisms underlying development of type 2 diabetes </studytitle>
    <scientifictitle>The significance of hyperglycaemia in survivors of critical illness and potential mechanisms underlying development of type 2 diabetes </scientifictitle>
    <utrn>NA</utrn>
    <trialacronym>NA</trialacronym>
    <secondaryid>NA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Critical Illness</healthcondition>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <healthcondition>Hyperglycaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Blood test (HBA1c &amp; Fasting Lipids), Oral Glucose tolerance test , Isotope breath test and height, weight and blood pressure will be measured at 3 months, 1, 2, 3, 6 and 10 years of health and unhealthy volunteers.</interventions>
    <comparator>NA</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Development of Type 2 Diabetes (assessed by Oral Glucose tolerance test and HbA1c blood test)</outcome>
      <timepoint>3 months, 1,2,3,6,10 years post hospital discharge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Measurement of glucose intolerance via oral glucose tolerance test, HBA1c levels and fasting lipds</outcome>
      <timepoint>3 months, 1,2,3,6,10 years post hospital discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Critical Illness-associated hyperglycaemia: HbA1c &lt; 6.5%, blood glucose concentrations &gt; 11.1 mmol/l for at least two consecutive readings during ICU admission
Normoglycaemic: HbA1c &lt; 6.5%, fasted blood glucose concentrations remain &lt; 7.1mmol/l and random concentrations remain &lt; 11.1 mmol/l throughout ICU admission
Healthy volunteers: &gt;18 years of age, sex and BMI will be used to match volunteers</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to give informed consent, current pregnancy, previous gestational diabetes, acute or chronic pancreatitis, medications known to affect glucose metabolism (e.g. steroids) </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Power calculations were completed</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Case control</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>31/03/2014</anticipatedstartdate>
    <actualstartdate>27/03/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Adam Deane</primarysponsorname>
    <primarysponsoraddress>ICU Research, Royal Adelaide Hospital
North Tce, Adelaide, SA, 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress>NA</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Conditions of temporary glucose intolerance - such as gestational diabetes - identify people who are at risk from subsequently developing type 2 diabetes. This is important as the prompt diagnosis of glucose intolerance allows earlier treatment and a consequent reduction in complications associated with prolonged and untreated hyperglycaemia, dyslipidaemia and hypertension. The possibility that critical illness-associated hyperglycaemia (CIAH) could be a risk factor for subsequent type 2 diabetes has only been evaluated in one study.  This study however has substantial limitations, which severely restrict interpretation of these data. If CIAH is a risk factor for development of type 2 diabetes, and the mechanisms underlying any glucose intolerance elucidated, survivors could be screened for diabetes and prompt appropriate therapy instituted.</summary>
    <trialwebsite>NA</trialwebsite>
    <publication>NA</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>NA</publicnotes>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Ethics Committee</ethicname>
      <ethicaddress>Royal Adelaide Hospital 
North Terrace, Adelaide, 5000
South Australia</ethicaddress>
      <ethicapprovaldate>3/03/2014</ethicapprovaldate>
      <hrec>131217</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Palash Kar</name>
      <address>Intensive Care Unit, Royal Adelaide Hospital
North Tce
Adelaide  5000
South Australia</address>
      <phone>+6188222 2818</phone>
      <fax />
      <email>p_kar@hotmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Palash Kar</name>
      <address>Intensive Care Unit, Royal Adelaide Hospital
North Tce
Adelaide  5000
South Australia</address>
      <phone>+6188222 2818</phone>
      <fax />
      <email>p_kar@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Palash Kar</name>
      <address>Intensive Care Unit, Royal Adelaide Hospital
North Tce
Adelaide  5000
South Australia</address>
      <phone>+6188222 2818</phone>
      <fax />
      <email>p_kar@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Palash Kar</name>
      <address>Intensive Care Unit, Royal Adelaide Hospital
North Tce
Adelaide  5000
South Australia</address>
      <phone>+6188222 2818</phone>
      <fax />
      <email>p_kar@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>